Skip to main content
. 2018 Jan 11;11:323–335. doi: 10.2147/OTT.S154395

Figure 2.

Figure 2

Cytoplasmic β-catenin immunoreactivity.

Notes: (A) Negative control (no primary antibody); (B) negative; (C) weak; (D) moderate; (E) invasive lobular breast carcinoma. Panels (AD) are invasive ductal carcinomas.